Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age ≥ 35 weeks~* diagnosis of TTN, defined as respiratory rate \>60, presence of subcostal and /or intercostal retractions, nasal flaring, grunting, oxygen saturations 70-93% on room air, and radiological evidence of perihilar streaking and patchy infiltrates~* admission to the NICU at Mount Sinai hospital within first 24 hours of life~Exclusion Criteria:~* gestational age \< 35 weeks~* history of thick meconium stained fluid and/or diagnosis of meconium aspiration syndrome~* diagnosis of major congenital pulmonary or cardiac anomalies~* initial CXR demonstrating air leak~* respiratory distress first occurring after 24 hours of life~* presumptive diagnosis of RDS as indicated by the need for FiO2 \> 40%, severe retractions and grunting with poor air entry, and diffuse alveolar consolidation on chest radiograph

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- High Flow Nasal Cannula (Type: EXPERIMENTAL): Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
- Control Group- Bubble Nasal CPAP (Type: ACTIVE_COMPARATOR): NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.

Based on this trial design, predict the completion outcome and termination type (if applicable).